Viking Therapeutics offered ‘transformative’ Q3 update, says Cantor Fitzgerald

Cantor Fitzgerald tells investors after Viking Therapeutics (VKTX)’ “transformative” Q3 update that “this was the most bullish update Viking has given since we started covering the stock more than 7 years ago.” Viking “just crystallized five critically important data catalysts in the next 24 months” and the company affirmed cash on hand of greater than $700M was sufficient to get through all of them, according to the analyst, who has an Overweight rating and $105 price target on Viking shares.